Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004867 · ClinicalTrials.gov registry record · NA

Positron Emission Tomography in Determining Stage of Esophageal Cancer

A NA study, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
NA
Development phase
235
Enrollment target

NCT00004867 is a NA study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 235 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004867, a NA study, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
NA
Development phase
235 participants
Enrollment target

Study Summary

RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer.

Interventions

  • RADIATION fludeoxyglucose F 18
  • PROCEDURE positron emission tomography
  • PROCEDURE conventional surgery
  • PROCEDURE radionuclide imaging
  • DRUG chemotherapy

Trial Details

FieldValue
Enrollment Target 235 participants
Start Date 1999-11
Est. Completion 2009-01
Phase NA

What the Registry Record Tells You About NCT00004867

The ClinicalTrials.gov registry entry for NCT00004867 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which fludeoxyglucose F 18 is the first listed.

NCT00004867 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00004867 about?

NCT00004867 is a clinical study titled "Positron Emission Tomography in Determining Stage of Esophageal Cancer". RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer.

What is the current status of trial NCT00004867?

This trial is currently completed. It is a NA study. The enrollment target is 235 participants. The study started on 1999-11. Estimated completion is 2009-01.

What interventions are being tested in trial NCT00004867?

The interventions under investigation include: fludeoxyglucose F 18 (RADIATION), positron emission tomography (PROCEDURE), conventional surgery (PROCEDURE), radionuclide imaging (PROCEDURE), chemotherapy (DRUG).

Who is sponsoring clinical trial NCT00004867?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.